Item 5. Market for Registrant’s Common Equity
ITEM
5 - MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market
Information
Our
common stock is listed on the NYSE American LLC Exchange, where it trades under the symbol “DSS”.
Holders
of Record
As
of March 14, 2022, we had 256 record holders of our common stock. This number does not include the number of persons whose
shares are in nominee or in “street name” accounts through brokers.
24
Dividends
We
did not pay dividends during 2021 or 2020. We anticipate that we will retain any earnings and other cash resources for investment in
our business. The payment of dividends on our common stock is subject to the discretion of our board of directors and will depend on
our operations, financial position, financial requirements, general business conditions, restrictions imposed by financing arrangements,
if any, legal restrictions on the payment of dividends and other factors that our board of directors deems relevant.
However,
the Company has announced its decision to issue shares of Impact BioMedical, Inc. to its shareholders of record at a to be determined
record date that will correspond with the registration of Impact BioMedical’s common stock. The Company announced that it intended
to issue four (4) shares of Impact BioMedical stock for each share of DSS common stock held by DSS shareholders (with the exception of
shares beneficially held by Alset International Ltd).
Securities
Authorized for Issuance Under Equity Compensation Plans
As
of December 31, 2021, securities issued and securities available for future issuance under both our 2013 and 2020 Employee, Director
and Consultant Equity Incentive Plan (the “Plans”) is as follows:
Restricted
stock to be issued upon vesting
Number
of securities to be issued upon exercise of outstanding options, warrants and rights
Weighted
average exercise price of outstanding options, warrants and rights
Number
of securities
remaining
available for
future
issuance (under
equity
compensation
Plans
(excluding
securities
reflected in
column
(a & b))
Plan
Category
(a)
(b)
(c)
(d)
Equity compensation plans approved by security
holders
2013 Employee,
Director and Consultant Equity Incentive Plan - options
-
11,930
$ 218.39
-
2013 Employee, Director
and Consultant Equity Incentive Plan - warrants
-
3,556
$ 30.00
-
2020
Employee, Director and Consultant Equity Incentive Plan
-
-
$ -
483,125
Total
-
15,486
$ 175.13
483,125
The
warrants listed in the table above were issued to third party service providers in partial or full payment for services rendered and
in conjunction with third party funding agreements.
Recent
Issuances of Unregistered Securities
Information
regarding any equity securities we have sold during the period covered by this Report that were not registered under the Securities Act
of 1933, as amended, and was not included in a quarterly report on Form 10-Q or in a current report on Form 8-K, is set forth below.
Each such transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities
Act or Rule 506 of Regulation D promulgated by the SEC, unless otherwise noted. Unless stated otherwise: (i) the securities were offered
and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii)
each of the persons who received these unregistered securities had knowledge and experience in financial and business matters which allowed
them to evaluate the merits and risk of the receipt of these securities, and that they were knowledgeable about our operations and financial
condition; (iv) no underwriter participated in, nor did we pay any commissions or fees to any underwriter in connection with the transactions;
and, (v) each certificate issued for these unregistered securities contained a legend stating that the securities have not been registered
under the Securities Act and setting forth the restrictions on the transferability and the sale of the securities.
Shares
Repurchased by the Registrant
We
did not purchase or repurchase any of our securities in the fiscal year ended December 31, 2021, including the fourth quarter.
ITEM
6 - SELECTED FINANCIAL DATA
Not
applicable.
25